Please assess the completion status of the following clinical trial:

Trial Title: Pilot Study of Sucrose to Reduce Pain in Sick Babies

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Infants who are inpatients of the NICU:~* Who are receiving a continuous intravenous infusion of an opioid analgesic such as morphine or fentanyl at a maximum dose equivalent to 20 mcg/kg/hr of morphine and;~* Who require heel lance for medically required blood sampling or nasogastric/orogastric (NG/OG) tube insertions and;~* Who are eligible to receive sucrose as per the hospital's Sucrose policy for infants.~Exclusion Criteria:~* Infants less than 25 weeks gestation~* Infants with any injury to the skin where the probe needs to be placed~* Infants with an implanted defibrillator or pacemaker~* Infants with an injury affecting sympathetic nerve conduction~* Infants exposed to antenatal methadone~* Infants who, aside from being on opioid analgesics, are ineligible to receive sucrose as per the hospital's Sucrose policy38~* If the infant's mother wishes to breastfeed during the procedure~* Infants with known or suspected fructose intolerance~* Infants with spinal cord malformation (e.g. myelomeningocele and sacral teratoma) since these infant's response, and sensitivity to pain may differ from infants without spinal cord malformations~* Infants who are unconscious, heavily sedated and those with absent gag and/or swallow reflex~* Infants who are in isolation with only essential personnel caring for them~* To ensure there is no interaction effect of muscle relaxants, which may impact on infants' ability to mount a behavioural response to pain, assessments will not be conducted until a period of 24 hours since the previous muscle relaxant dose~* Parental language barrier (if unable to speak/understand French and/or English)

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Sucrose 24% po (Type: EXPERIMENTAL): 24% sucrose solution. The Children's Hospital of Eastern Ontario (CHOE) pharmacy department will provide syringes labeled NICU Pain Relief Study containing a maximum dose of 1 mL of a 24% sucrose solution
- Placebo po (Type: PLACEBO_COMPARATOR): The CHEO pharmacy department will provide a syringe labeled NICU Pain Relief Study containing a maximum of 1 ml dose of water (contents almost identical in color, consistency and odor to the sucrose solution) in identical packagings

Based on this trial design, predict the completion outcome and termination type (if applicable).